Exagen Financial Statements From 2010 to 2026

XGN Stock

USD 3.51 0.15 4.46%

Exagen's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Exagen's valuation are provided below:

Gross Profit

38.1 M

Profit Margin

(0.30)

Market Capitalization

76.1 M

Enterprise Value Revenue

1.0941

Revenue

63.6 M

We have found one hundred twenty available fundamental signals for Exagen Inc, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Exagen's prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 6th of February 2026, Enterprise Value is likely to grow to about 71.4 M, while Market Cap is likely to drop about 37.1 M.

Exagen Total Revenue

34.58 Million

Check Exagen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Exagen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Interest Expense of 2.8 M or Selling General Administrative of 29.1 M, as well as many indicators such as Price To Sales Ratio of 1.33, Dividend Yield of 0.0169 or PTB Ratio of 7.39. Exagen financial statements analysis is a perfect complement when working with Exagen Valuation or Volatility modules.

Build AI portfolio with Exagen Stock

Check out the analysis of Exagen Correlation against competitors.

Exagen Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

53.8 M

51.4 M

43.2 M

Slightly volatile

Short and Long Term Debt Total

24 M

26.5 M

19.8 M

Slightly volatile

Other Current Liabilities

5.5 M

9 M

4.6 M

Slightly volatile

Total Current Liabilities

9.8 M

12.2 M

10.5 M

Very volatile

Property Plant And Equipment Net

9.3 M

8.8 M

3.9 M

Slightly volatile

Current Deferred Revenue

3.4 M

2.3 M

2.7 M

Very volatile

Accounts Payable

5 M

4.8 M

2.2 M

Slightly volatile

Cash

35.9 M

25.3 M

27.6 M

Slightly volatile

Non Current Assets Total

10.1 M

9.5 M

9 M

Slightly volatile

Cash And Short Term Investments

35.9 M

25.3 M

27.6 M

Slightly volatile

Common Stock Shares Outstanding

22 M

20.9 M

8.1 M

Slightly volatile

Liabilities And Stockholders Equity

53.8 M

51.4 M

43.2 M

Slightly volatile

Non Current Liabilities Total

20.6 M

24.9 M

17.6 M

Slightly volatile

Other Current Assets

8 M

7.6 M

3.1 M

Slightly volatile

Other Stockholder Equity

177.8 M

349.4 M

154.7 M

Slightly volatile

Total Liabilities

34.1 M

40.4 M

28.5 M

Slightly volatile

Property Plant And Equipment Gross

16.5 M

15.8 M

5.5 M

Slightly volatile

Total Current Assets

43.7 M

41.9 M

34.3 M

Slightly volatile

Short Term Debt

1.3 M

1.4 M

3.9 M

Slightly volatile

Common Stock

14.8 K

20.7 K

13.5 K

Slightly volatile

Other Assets

894.3 K

475.2 K

860.1 K

Pretty Stable

Net Receivables

6.3 M

9 M

4 M

Slightly volatile

Property Plant Equipment

15.8 M

15 M

5.3 M

Slightly volatile

Other Liabilities

16.2 K

17.1 K

1.2 M

Slightly volatile

Net Working Capital

52.7 M

26.4 M

30.6 M

Slightly volatile

Capital Stock

15.4 K

16.2 K

55.7 M

Slightly volatile

Exagen Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation And Amortization

1 M

2 M

923.7 K

Slightly volatile

Interest Expense

2.8 M

2.6 M

2.3 M

Slightly volatile

Selling General Administrative

29.1 M

46 M

24.7 M

Slightly volatile

Selling And Marketing Expenses

1.5 M

1.6 M

1.3 M

Slightly volatile

Total Revenue

34.6 M

64 M

29.7 M

Slightly volatile

Other Operating Expenses

51.2 M

79.7 M

43.6 M

Slightly volatile

Research Development

3.8 M

6.2 M

3.2 M

Slightly volatile

Cost Of Revenue

16.2 M

25.9 M

13.9 M

Slightly volatile

Total Operating Expenses

35 M

53.8 M

29.7 M

Slightly volatile

Interest Income

947.5 K

690.3 K

895.6 K

Very volatile

Reconciled Depreciation

1.2 M

2 M

991.2 K

Slightly volatile

Exagen Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Stock Based Compensation

1.8 M

2 M

1.4 M

Slightly volatile

Begin Period Cash Flow

34.5 M

42.2 M

27.3 M

Slightly volatile

Depreciation

1 M

2 M

923.7 K

Slightly volatile

Capital Expenditures

1.1 M

592.2 K

872.6 K

Slightly volatile

End Period Cash Flow

36 M

25.6 M

27.7 M

Slightly volatile

Change To Netincome

14.3 M

13.6 M

6.9 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

1.33

1.21

1.4065

Pretty Stable

Dividend Yield

0.0169

0.019

0.0208

Slightly volatile

Days Sales Outstanding

38.16

46.26

32.8093

Slightly volatile

Stock Based Compensation To Revenue

0.0404

0.0285

0.0548

Slightly volatile

Capex To Depreciation

0.26

0.27

0.9257

Pretty Stable

EV To Sales

1.27

1.22

1.3531

Pretty Stable

Inventory Turnover

22.57

17.31

20.7713

Slightly volatile

Days Of Inventory On Hand

15.32

21.83

18.7826

Slightly volatile

Payables Turnover

5.84

4.9

6.9276

Pretty Stable

Sales General And Administrative To Revenue

1.47

0.83

1.7063

Slightly volatile

Research And Ddevelopement To Revenue

0.22

0.11

0.3002

Slightly volatile

Capex To Revenue

0.0101

0.0106

0.1083

Slightly volatile

Cash Per Share

1.32

1.39

64.1414

Slightly volatile

Days Payables Outstanding

62.27

77.08

58.3063

Pretty Stable

Income Quality

0.6

0.79

0.7583

Pretty Stable

Intangibles To Total Assets

0.0487

0.0513

0.2428

Slightly volatile

Current Ratio

3.72

2.43

3.9748

Slightly volatile

Receivables Turnover

7.76

8.17

27.3299

Slightly volatile

Capex Per Share

0.0309

0.0325

5.0932

Slightly volatile

Revenue Per Share

3.34

3.52

119

Pretty Stable

Interest Debt Per Share

1.51

1.59

144

Slightly volatile

Debt To Assets

0.69

0.59

0.6038

Very volatile

Operating Cycle

41.57

46.26

37.7415

Slightly volatile

Days Of Payables Outstanding

62.27

77.08

58.3063

Pretty Stable

Ebt Per Ebit

1.58

1.27

1.508

Pretty Stable

Total Debt To Capitalization

0.77

0.81

1.2559

Pretty Stable

Quick Ratio

3.7

2.43

3.9541

Slightly volatile

Net Income Per E B T

1.1

1.15

1.0146

Slightly volatile

Cash Ratio

1.39

1.47

3.1699

Slightly volatile

Days Of Inventory Outstanding

15.32

21.83

18.7826

Slightly volatile

Days Of Sales Outstanding

38.16

46.26

32.8093

Slightly volatile

Free Cash Flow Operating Cash Flow Ratio

0.85

0.93

1.0386

Slightly volatile

Fixed Asset Turnover

9.29

6.52

10.4221

Pretty Stable

Debt Ratio

0.69

0.59

0.6038

Very volatile

Price Sales Ratio

1.33

1.21

1.4065

Pretty Stable

Asset Turnover

0.58

1.12

0.6984

Slightly volatile

Exagen Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

37.1 M

67.2 M

46.1 M

Slightly volatile

Enterprise Value

71.4 M

68 M

41.9 M

Slightly volatile

Exagen Fundamental Market Drivers

Exagen Upcoming Events

	18th of March 2024 Upcoming Quarterly Report	View
	20th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	18th of March 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Exagen Financial Statements

Exagen investors utilize fundamental indicators, such as revenue or net income, to predict how Exagen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Current Deferred Revenue	2.3 M	3.4 M
Total Revenue	64 M	34.6 M
Cost Of Revenue	25.9 M	16.2 M
Stock Based Compensation To Revenue	0.03	0.04
Sales General And Administrative To Revenue	0.83	1.47
Research And Ddevelopement To Revenue	0.11	0.22
Capex To Revenue	0.01	0.01
Revenue Per Share	3.52	3.34
Ebit Per Revenue	(0.22)	(0.23)

Pair Trading with Exagen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Exagen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exagen will appreciate offsetting losses from the drop in the long position's value.

Moving together with Exagen Stock

0.75	DWTX	Dogwood Therapeutics	Pair Corr
0.9	EDIT	Editas Medicine	Pair Corr

Moving against Exagen Stock

0.88	DSGN	Design Therapeutics	Pair Corr
0.8	IMMP	Immutep Ltd ADR	Pair Corr
0.79	ENGN	enGene Holdings Common	Pair Corr
0.64	KYTX	Kyverna Therapeutics	Pair Corr
0.54	63E	ONWARD MEDICAL BV	Pair Corr

The ability to find closely correlated positions to Exagen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Exagen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Exagen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Exagen Inc to buy it.

The correlation of Exagen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exagen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exagen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Exagen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock:

How To Invest In Exagen

Details

Is Exagen Stock a good investment?

Details

What is Exagen's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Exagen Correlation against competitors.

You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Will Biotechnology sector continue expanding? Could Exagen diversify its offerings? Factors like these will boost the valuation of Exagen. Anticipated expansion of Exagen directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Exagen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Earnings Share

(0.90)

Revenue Per Share

3.138

Quarterly Revenue Growth

0.379

Return On Assets

(0.15)

Return On Equity

(1.23)

Investors evaluate Exagen Inc using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Exagen's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Exagen's market price to deviate significantly from intrinsic value.

Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Exagen's market price signifies the transaction level at which participants voluntarily complete trades.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Exagen Financial Statements From 2010 to 2026

Exagen Total Revenue

34.58 Million

Exagen Balance Sheet

Exagen Income Statement

Exagen Cash Flow Statement

Financial Ratios

Exagen Valuation Data

Exagen Fundamental Market Drivers

Exagen Upcoming Events

About Exagen Financial Statements

Pair Trading with Exagen

Moving together with Exagen Stock

Moving against Exagen Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY